OncoSec Enters Into Collaboration Agreement With Merck For A Pivotal Global Phase 3 Study, KEYNOTE-C87, Of TAVO Combined With KEYTRUDA For Late-Stage Metastatic Melanoma
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it has entered into a Clinical Trial Collaboration and Supply Agreement ("Agreement") with Merck